ALK rearrangements are found in approximately 5% of NSCLC patients, and currently, five ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) are FDA-approved for this indication [98]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.